retatrutide clinical trial phase 3: TRIUMPH Program Results 2026 Retatrutide Phase 3 Results: Trials,

Per the Ridha 2024 Aesthetic Surgery Journal paper (PMID 38874170), the temporal fat pad is among the most affected compartments

GLP-1 receptors are highly expressed on rodent C-cells, and chronic stimulation caused proliferation and tumor formation

The overall difference between orforglipron and placebo was approximately 5 kg

If chest pain persists beyond 48 hours, worsens despite conservative care, or develops new concerning features, schedule an urgent evaluation with your primary care physician or seek emergency department assessment

Sublingual GLP-1 drops have gained attention as a needle-free alternative to injectable semaglutide and tirzepatide